Incyte (INCY) Azione Prezzo
Incyte Prezzo
Negli ultimi 19 anni Incyte ha aumentato il fatturato del 31,7% all'anno, raggiungendo 5,14 miliardi USD. L'utile per azione è cresciuto del 68,6% all'anno negli ultimi 10 anni. Per Incyte, il margine netto del 25,0% risulta in calo rispetto al 31,8% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Incyte è 130,00 USD, circa il 5,4% sopra il prezzo attuale di mercato. Su 35 analisti, 18 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Incyte Prezzo delle azioni
Incyte Azione e analisi azionaria
Domande frequenti sull'azione Incyte
The business model of Incyte Corp revolves around discovering, developing, and commercializing novel medicines to address the needs of patients with serious diseases. As a leading biotechnology company, Incyte focuses on discovering and developing small molecule drugs that target specific biological pathways involved in diseases such as cancer and immune-inflammatory disorders. By leveraging its expertise in genomics and medicinal chemistry, Incyte aims to bring innovative treatments to market, improving patients' lives worldwide. Through collaborations and partnerships, Incyte also strives to expand its product portfolio and accelerate its pipeline of promising therapies.
Incyte Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Incyte Corp in the market are Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc.
Incyte Corp is a leading biopharmaceutical company based in the United States. Founded in 1991, it has established a strong reputation in the field of drug discovery and development. Incyte Corp primarily focuses on the discovery, development, and commercialization of innovative therapies to address various unmet medical needs. Throughout its history, the company has been committed to advancing scientific knowledge, and it has successfully launched several drugs targeting different diseases. With a dedicated team of researchers and professionals, Incyte Corp continues to make significant contributions to the healthcare industry, aiming to improve the lives of patients worldwide.
Incyte Corp has achieved several significant milestones in its history. One notable achievement is the development and approval of its flagship drug, Jakafi® (ruxolitinib), by the U.S. Food and Drug Administration (FDA) in 2011. Jakafi® is the first and only FDA-approved treatment for certain types of rare blood cancers. Additionally, Incyte Corp has made advancements in the field of oncology with the discovery and development of multiple innovative drugs, aiming to improve the lives of patients with various types of cancer. The company continues to expand its pipeline and collaborate with leading research institutions, further establishing itself as a prominent player in the biopharmaceutical industry.
Incyte Corp is primarily present in various countries and regions globally. The company has a widespread presence in the United States, where its headquarters are located in Wilmington, Delaware. Additionally, Incyte Corp has established its significant presence in Europe, including countries such as the United Kingdom, Germany, France, Italy, and Spain. It has also expanded its operations in Asia-Pacific regions like Japan, China, and Singapore. Furthermore, Incyte Corp has been expanding its reach in Latin American countries such as Brazil and Mexico, as well as in Canada. Overall, Incyte Corp has a strong international presence, allowing it to cater to a global market.
Incyte Corp represents values centered around innovation, collaboration, and integrity. The company prioritizes scientific excellence and is dedicated to discovering and developing transformative medicines for patients. Incyte Corp fosters a corporate philosophy that emphasizes the importance of putting patients first, embracing diversity and inclusion, and maintaining high ethical standards. With a focus on research and development, Incyte Corp strives to make a positive impact on the lives of patients and the healthcare industry as a whole.
Gli analisti fissano attualmente un prezzo obiettivo medio di 128,38 USD per l’azione Incyte (mediana: 130,00 USD), pari a +3,6 % rispetto all’ultimo prezzo. Il consenso si basa su 35 giudizi di analisti.
35 analisti valutano attualmente l’azione Incyte: 18 raccomandano l’acquisto, 17 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Incyte ricavi pari a 5,94 miliardi USD e un utile per azione di 3,69 USD.
Convertita al tasso di cambio attuale, l’azione Incyte quota 108,40 EUR (123,29 USD).
L’azione Incyte (INCY) è quotata su 8 borse, tra cui: NASDAQ (INCY), London (0J9P.L), SIX (Zürich) (ICY.SW), Frankfurt (ICY.F), München (ICY.MU), Düsseldorf (ICY.DU).
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and marketing of drugs to help patients with serious diseases. The company is headquartered in Wilmington, Delaware, USA, and operates subsidiaries in Europe and Asia. Its business model is based on developing therapies to combat serious diseases such as cancer, inflammation, and autoimmune diseases through targeted therapy that attacks specific molecules in the body to reduce tumor spread or inflammatory reactions. Incyte Corp has a wide range of products that treat various diseases, with its flagship product being Jakafi® (Ruxolitinib), a drug for treating myelofibrosis and polycythemia vera. It also has a strong pipeline of new drugs in development, including Itacitinib for treating graft-versus-host disease and INCMGA00012 for treating solid tumors. The company is investing in digitization and data analysis to optimize its research and development efforts, and has various business segments including research and development, sales and marketing, clinical studies, and others. It distributes its products directly to clinics and hospitals as well as indirectly through wholesalers and distribution partners, and has formed partnerships with other companies in the industry to enhance research and development and expand global market access. In summary, Incyte Corp is dedicated to discovering, developing, and marketing drugs for patients with serious diseases, with a broad product range, strong partnerships, and a pipeline of new drugs in development. The company is dedicated to using data to improve patient care.
Il attesa fatturato di Incyte ammonta a 5,94 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Incyte ammonta a 755,10 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Incyte è attualmente 33,43. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Incyte.
Il rapporto prezzo/fatturato (P/S) di Incyte è attualmente 4,25. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Incyte.
Il Quality Score AlleAktien per Incyte è 6/10.
L'ISIN di Incyte è US45337C1027. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Incyte è 896133. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Incyte è INCY. Con questo simbolo di borsa vengono negoziate le azioni Incyte in borsa.
Azione Incyte
Gruppo di pari di Incyte
Incyte Ticker
Incyte FIGI
Altre metriche e analisi di Incyte in Deep Dive.
La nostra analisi azionaria dell'azione Incyte include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Incyte. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: